Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCD1 | P51178 | 1/20 | 0.48 |
| ▸ | HLCS | P50747 | 3/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.45 |
| ▸ | FGF1 | P05230 | 1/20 | 0.43 |
| ▸ | FGF2 | P09038 | 1/20 | 0.43 |
| ▸ | VEGFA | P15692 | 1/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
| ▸ | HINT1 | P49773 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14406729 | 1.00 | PLCD1 (0.48) | PLCD1HLCSP2RY6P2RY2FGF1 | |
| SCHEMBL12994951 | 1.00 | PLCD1 (0.48) | PLCD1HLCSP2RY6P2RY2FGF1 | |
| SCHEMBL14406723 | 0.94 | PLCD1 (0.47) | PLCD1HLCSP2RY6P2RY2FGF1 | |
| SCHEMBL20129499 | 0.92 | PLCD1 (0.49) | PLCD1HLCSFGF1FGF2VEGFA | |
| SCHEMBL29426309 | 0.91 | PLCD1 (0.49) | PLCD1HLCSFGF1FGF2VEGFA | |
| SCHEMBL12994950 | 0.90 | KRAS (0.54) | HLCSP2RY6P2RY2F2 | |
| SCHEMBL13050628 | 0.90 | KRAS (0.54) | HLCSP2RY6P2RY2F2 | |
| SCHEMBL29627228 | 0.90 | PLCD1 (0.47) | PLCD1HLCSFGF1FGF2VEGFA | |
| SCHEMBL13050995 | 0.89 | HLCS (0.51) | PLCD1HLCSP2RY6P2RY2FGF1 | |
| SCHEMBL12994968 | 0.89 | HLCS (0.51) | PLCD1HLCSP2RY6P2RY2FGF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120156751-A1 | PREPARATION AND ISOLATION OF 5' CAPPED MRNA | APPLIED BIOSYSTEMS, LLC (US) | 2012-06-21 | — | — | US | disclosed |
| US-20100304389-A1 | Preparation And Isolation of 5' Capped mRNA | Life Technologies Corporation (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100304389-A1 | Preparation And Isolation of 5' Capped mRNA | RNGTT, RNMT, NSUN2 | PLCD1 1718/4885HLCS 1803/4885P2RY6 4160/4885 |
| US-20120156751-A1 | PREPARATION AND ISOLATION OF 5' CAPPED MRNA | RNGTT, RNMT, NSUN2 | PLCD1 1718/4885HLCS 1803/4885P2RY6 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.